The first is by the eminent schizophrenia researcher and editor of The American Journal of Psychiatry, Dr Nancy Andreasen. Dr Andreasen summarizes what is currently known about the workings of the brain in schizophrenia and provides a unifying theory of pathophysiology with thalamic (from the Greek, meaning "marriage bed") projections constituting the tangled bed linen in which schizophrenia malfunction is conceived.
Dr Andreasen reviews the history of the search for neural mechanisms that might explain the diverse mental phenomena associated with schizophrenia and the requirement, in the interests of parsimony, of locating a single cognitive process that lies at the core of the schizophrenia deficit. In the language of current neuroscience, she postulates that distributed parallel processing is responsible for brain functioning and that these parallel processes are mediated via interconnected neural circuits. When several circuits seem to go awry, as in schizophrenia, it is logical to look for one crucial brain region or "switchboard" that has become faulty. The thalamus fits the bill as a potential candidate for this critical function. Dr Andreasen describes the role of the thalamus and its multiple projections in normal brain functioning. She then proposes a theory of "cognitive dysmetria" in schizophrenia founded on a defect in prefrontal-thalamic-cerebellar circuitry and provides evidence for thalamic abnormalities in patients with schizophrenia. She concludes her must-read, lucidly written overview with the thought that thalamic circuitry, while perhaps playing a key role in the integration of thinking and responding, is probably only one of the complex distributed circuits of the brain which are "dysmetric" or unbalanced in the profoundly complex brain disturbance we diagnose as schizophrenia.
The complexities of this illness are reflected in its varied outcomes. The second review article is contributed by Drs Larry Davidson and Tom McGlashan of the Yale University School of Medicine. These masters of data analysis review the heterogeneous outcomes among different individuals with schizophrenia; they note that outcomes vary across geographic space and historical time; and they describe intraindividual differences, that is, differences found in any one person in the various successes and failures which we group together under the term "outcome." This review analyzes outcome research since 1988, with a special focus on prospective studies of first-episode patients, on cross-cultural and historic trends, on long-term follow-up, and on discrete domains of functioning.
The authors point out that the conclusions of study reports need to keep methodological shortcomings in mind. They identify the most important shortcomings as bearing on the clarity and definition of diagnostic criteria, as well as on the operational meaning of such terms as "prodrome," "onset," and "recovery." They also address sample biases, comparison groups, the interplay of disease process and treatment effect, and the complexities of culture and of practical logistics in the conduct of long-term follow-ups of large-scale populations.
Nevertheless, they underscore the important conclusions that can be drawn from integrating knowledge across the broad range of recent study reports. First, a significant amount of deterioration in those whose long-term outcome turns out to be poor has already occurred early in the process, as early as the first episode, if not before. Second, the deficit syndrome remains relatively stable over time and is associated with cognitive impairment and both work and social disability. Third, cross-cultural and historical differences in outcome need to be better understood. Fourth, it may be feasible to identify young people at high risk for psychosis and to intervene early, thus reducing the duration of untreated psychosis and improving long-term outcome. Fifth, recent studies confirm earlier reports that the individual with schizophrenia who suffers early deterioration reaches, with time, an illness plateau and may improve thereafter. Sixth, the "narrower" the diagnostic criteria, the worse the prognosis. Seventh, early response to treatment and assertive rehabilitation improve prognosis. These are important consensus findings, and they are particularly useful to clinicians since they encourage us to treat actively and early and not to lose hope prematurely.
Two other articles in this issue address the problem of schizophrenia (3, 4) . In the older outcome literature, it was shown that substance abuse of any kind constitutes a negative prognostic factor. In this issue, Addington and others explore the motivation of schizophrenia patients to stop smoking and find that it is possible to predict which patients are motivated to do so and which methods are effective.
The article by Remington and others explores a historical trend (the last decade) in neuroleptic prescribing and concludes that patients with schizophrenia tend to be prescribed progressively higher neuroleptic doses over the duration of their illness. This is particularly interesting in the context of the outcome literature, which confirms a "plateauing" of severity of symptoms with time, followed by actual improvement in a significant minority of patients. In other words, neuroleptic doses should, by rights, be going down. It may be that a sample recruited from a tertiary hospital is unique in the sense that illness severity may, in fact, be increasing over time. A warning to clinicians is in order: even if, retrospectively, large doses may not have been required, decreasing such doses in order to conform to what has now become more standard practice poses clinical risks of relapse and dyskinesias that need careful consideration and attention.
Subsequent review articles in this series will deal with psychopharmacology, tardive dyskinesia, neurocognition, and epidemiology. The Journal and its readers are fortunate to be able to look forward to comprehensive, up-to-date, readable, integrative papers covering the full current scope of knowledge in schizophrenia research.
